Format

Send to

Choose Destination
Antivir Ther. 2006;11(4):397-408.

Future therapies for hepatitis C.

Author information

1
Department of Virology, INSERM U635, Henri Mondor Hospital, University of Paris, Créteil, France.

Abstract

Although pegylated interferon-alpha plus ribavirin has become the standard for treating chronic hepatitis C virus infection, a substantial number of patients do not tolerate therapy and require dose reduction or discontinuation, or do not respond to this combination therapy. Thus, new therapeutic options are needed. An increased knowledge of the hepatitis C virus and an understanding of its replication cycle, as well as advances in biotechnology, have stimulated the development of numerous new antiviral treatments for patients with hepatitis C virus infection. This review focuses on four classes of new agents: new interferons, ribavirin-like molecules, specific small-molecule hepatitis C virus inhibitors and new immune therapies, with particular emphasis on medications in the later stages of development.

PMID:
16856613
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center